title: 'Real-world' effectiveness of smoking cessation treatments: a population study.
abstract: OBJECTIVE
  There is a need for more evidence on the 'real-world' effectiveness of commonly used aids to smoking cessation from population-level studies. This study assessed the association between abstinence and use of different smoking cessation treatments after adjusting for key potential confounding factors.
  
  
  METHODS
  Cross-sectional data from aggregated monthly waves of a household survey: the Smoking Toolkit Study.
  
  
  METHODS
  England.
  
  
  METHODS
  A total of 10 335 adults who smoked within the previous 12 months and had made at least one quit attempt during that time.
  
  
  METHODS
  Participants were classified according to their use of cessation aids in their most recent quit attempt: (i) medication (nicotine replacement therapy, bupropion or varenicline) in combination with specialist behavioural support delivered by a National Health Service Stop Smoking Service; (ii) medication provided by the prescribing health-care professional without specialist behavioural support; (iii) nicotine replacement therapy (NRT) bought over the counter; and (iv) none of these. The main outcome measure was self-reported abstinence up to the time of the survey, adjusted for key potential confounders including tobacco dependence.
  
  
  RESULTS
  Compared with smokers using none of the cessation aids, the adjusted odds of remaining abstinent up to the time of the survey were 3.25 [95% confidence interval (CI) = 2.05-5.15] greater in users of prescription medication in combination with specialist behavioural support, 1.61 (95% CI = 1.33-1.94) greater in users of prescription medication combined with brief advice and 0.96 (95% CI = 0.81-1.13) in users of NRT bought over the counter.
  
  
  CONCLUSIONS
  After adjusting for major confounding variables such as tobacco dependence, smokers in England who use a combination of behavioural support and pharmacotherapy in their quit attempts have almost three times the odds of success than those who use neither pharmacotherapy nor behavioural support. Smokers who buy nicotine replacement therapy over the counter with no behavioural support have similar odds of success in stopping as those who stop without any aid.
authors.affiliation: Department of Family Medicine, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, the Netherlands; Cancer Research UK Health Behaviour Research Centre, University College London, London, UK.
authors.forename: Daniel
authors.initials: D
authors.lastname: Kotz
authors.forename: Jamie
authors.initials: J
authors.lastname: Brown
authors.forename: Robert
authors.initials: R
authors.lastname: West
mesh_terms: D000328:Adult; D001521:Behavior Therapy; D001552:Benzazepines / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use*; D004739:England; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D011810:Quinoxalines / Q000627:therapeutic use*; D012907:Smoking / Q000628:therapy*; D016540:Smoking Cessation / Q000379:methods*; D061485:Tobacco Use Cessation Devices; D016896:Treatment Outcome; D000068580:Varenicline; D055815:Young Adult
chemical_list: D001552:Benzazepines; D018765:Dopamine Uptake Inhibitors; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline
keywords: Behavioural support; bupropion; national household survey; nicotine replacement therapy; smoking cessation; varenicline